ReviewAAPS PharmSciTech2026
Admixture Compatibility Studies in Parenteral Formulations: Packaging, Device, and Regulatory Perspectives.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Bioactive Polysaccharide-Small-Molecule Drug Supramolecular Nanocomplexes for Drug Delivery and Therapeutic Applications.Journal of functional biomaterials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parenteral therapies are vital in critical care, oncology, and nutrition, offering rapid onset, precise dosing, and high bioavailability. However, their safety is often compromised by admixture incompatibilities and drug-device interactions that threaten stability, efficacy, and patient outcomes. This review synthesizes the current scientific understanding of physicochemical and material-based incompatibilities in reconstituted formulations, intravenous drug admixtures, and parenteral nutrition, highlighting their implications for safety and efficacy. Key risks include precipitation, pH shifts, phase separation, leachables, particulates, and adsorption, with documented links to treatment failure, infusion reactions, and product recalls. Interactions with packaging systems-glass, plastics, elastomers, and siliconized components-are critically examined, alongside regulatory requirements for extractables, leachables, and container-closure integrity. Emerging strategies, such as advanced packaging materials, fluoropolymer-coated elastomers, and real-time monitoring technologies, are highlighted as pathways to safer parenteral therapy. By uniting clinical insights with regulatory requirements and emerging technologies, this review highlights admixture compatibility studies as essential to ensuring the safety, efficacy, and reliability of parenteral drug delivery.
Indexed as
Identifiers
41514061What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.